Modelling plasticity of cancer cells and emergence of drug-induced drug resistance using adaptive cell population dynamics, with perspectives in therapeutics

Jean Clairambault
Sorbonne Université, Jacques-Louis Lions Lab, UMR CNRS 7598, Paris, France
& MAMBA Inria team, Paris, France
jean.clairambault@inria.fr, http://who.rocq.inria.fr/Jean.Clairambault/

I will present an evolutionary viewpoint on cancer, seen at the two time scales of (large-time) evolution in the genomes and of (short-time) evolution in the epigenetic landscape of a constituted genome. These views, based on works by Lineweaver, Davies and Vincent (cancer as backward evolution in multicellular organisms, aka atavistic theory of cancer) and by Sui Huang and collaborators (revisited Waddington epigenetic landscape), respectively, may serve as guidelines to propose a global conception of cancer, including towards possible innovating therapeutic strategies. Drug-induced drug resistance, the biological and medical question we are tackling from a theoretical point of view, related to the plasticity of cancer cells, may be due to biological mechanisms of different natures, mere local regulation, epigenetic modifications (reversible) or genetic mutations (irreversible), according to the extent to which the genome of the cells in the population is affected. In this respect, the modelling framework of adaptive dynamics we will present is more likely to correspond biologically to epigenetic modifications, although eventual induction of emergent resistant cell clones due to mutations under drug pressure is never to be ex-
cluded. From the biologist's point of view, we study phenotypically heterogeneous, but genetically homogeneous, cancer cell populations under stress by drugs.
The built-in targets for theoretical therapeutic control present in the phenotype-structured PDE models we advocate are not supposed to represent well-defined molecular effects of the drugs in use, but rather functional effects, i.e., related to induction of cell death (cytotoxic drugs), or to proliferation in the sense of slowing down the cell division cycle without killing cells (cytostatic drugs). We propose that cell life-threatening drugs (cytotoxics) induce by far more resistance in the highly plastic cancer cell populations than drugs that only limit their growth (cytostatics), and that a rational combination of the two classes of drugs - and possibly others, adding relevant targets to the model - may be optimised to propose therapeutic control strategies to avoid the emergence of drug resistance in tumours. We address this optimal control problem in the context of two populations, healthy and cancer, both endowed with phenotypes evolving with drug pressure, and competing for space and nutrients in a non-local Lotka-Volterra-like way, taking thus into account a constraint of limiting unwanted adverse effects.
Finally, I will present some transdisciplinary challenges of cancer modelling that should concern mathematicians, cell biologists, evolutionary biologists and oncologists, aiming to go beyond the present state of the art in the treatments of cancer.

REFERENCES
[1] Nguyen, T.N., *JC*, Jaffredo, T., Perthame, B., Salort, D.
Adaptive dynamics of hematopoietic stem cells and their supporting stroma:
A model and mathematical analysis. Mathematical Biosciences, 16(5):4818-4845,

and Engineering (2019).

[2] *JC*, Pouchol, C. A survey of adaptive cell population dynamics models of emergence of drug resistance in cancer, and open questions about evolution and cancer. BIOMATH, 8(1) (2019).

[3] Pouchol, C., *JC*, Lorz, A., Trélat, E. Asymptotic study and optimal control of integrodifferential systems modelling healthy and cancer cells exposed to chemotherapy. Journal de Mathématiques Pures et Appliquées, 116:268-308 (2018).

[4] Goldman, A., Kohandel, M., *JC*. Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer, Part 1: Biological Facts and Studies in Drug Resistance, Current Stem Cell Reports, 3:253-259, and Part 2: From Theoretical Biology to Mathematical Models, Current Stem Cell Reports, 3:260-268 (2017).

[5] Chisholm, R.H., Lorenzi, T., *JC*. Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation. BBA General Subjects, 1860:2627-2645 (2016).

[6] Chisholm, R.H., Lorenzi, T., Lorz, A., Larsen, A.K., Almeida, L., Escargueil, A., *JC*. Emergence of reversible drug tolerance in cancer cell populations: an evolutionary outcome of selection, non-genetic instability and stress-induced adaptation. Cancer Research, 75(6):930-939 (2015).

[7] Lorz, A., Lorenzi, T., *JC*, Escargueil, A., Perthame, B. Effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. Bull. Math. Biol., 77(1):1-22 (2015).

[8] Lorz, A., Lorenzi, T., Hochberg, M.E., *JC*, Perthame, B. Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. Mathematical Modelling and Numerical Analysis, 47:377-399 (2013).